Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era Role of Scoring Systems

被引:31
|
作者
Goel, Aparna [1 ]
Kim, Woong Ray [1 ]
机构
[1] Stanford Univ, Div Gastroenterol & Hepatol, Alway Bldg,Room M211,300 Pasteur Dr, Stanford, CA 94305 USA
关键词
PBC; Ursodeoxycholic acid; Prognosis; Scoring systems; Predictive models; RANDOMIZED CONTROLLED-TRIALS; EARLY BIOCHEMICAL RESPONSE; LONG-TERM PROGNOSIS; DOUBLE-BLIND; HISTOLOGICAL PROGRESSION; TREATED PATIENTS; END-POINTS; FOLLOW-UP; CIRRHOSIS; SURVIVAL;
D O I
10.1016/j.cld.2018.03.007
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary biliary cholangitis (PBC) is a chronic disease that progresses to end-stage liver disease. Ursodeoxycholic acid (UDCA), the standard treatment for PBC for several decades, is associated with improved survival without liver transplant. Approximately 40% of patients do not respond to UDCA. Because of disease variability, there exist several prognostic models that incorporate various factors including biochemical response to UDCA. These models are useful for patient care and counseling as well as risk stratification for research and clinical trials, and the role of these models in the pre-UDCA and UDCA eras is discussed.
引用
收藏
页码:563 / +
页数:17
相关论文
共 50 条
  • [11] Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis
    Matsumoto, Kosuke
    Hirohara, Junko
    Takeuchi, Akihito
    Miura, Ryo
    Asaoka, Yoshinari
    Nakano, Toshiaki
    Tanaka, Atsushi
    HEPATOLOGY RESEARCH, 2023, 53 (10) : 989 - 997
  • [12] Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment
    Chen, Jialiang
    Xue, Dongying
    Gao, Fangyuan
    Tao, Le
    Li, Yuxin
    Zhang, Qun
    Wang, Rui
    Sun, Le
    Yang, Xue
    Liu, Yao
    Zhu, Bingbing
    Niu, Shuaishuai
    Wang, Xianbo
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (11) : 1352 - 1360
  • [13] Simplified 6-month prediction scores for primary biliary cholangitis patients treated with ursodeoxycholic acid
    Pinyopornpanish, Kanokwan
    Chadalavada, Pravallika
    Sarmini, Muhammad Talal
    Khoudari, George
    Alomari, Mohammad
    Padbidri, Vinay
    Romero-Marrero, Carlos
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (04) : 411 - 416
  • [14] Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
    Alomari, Mohammad
    Covut, Fahrettin
    Al Momani, Laith
    Chadalavada, Pravallika
    Hitawala, Asif
    Young, Mark F.
    Romero-Marrero, Carlos
    JGH OPEN, 2020, 4 (02): : 132 - 139
  • [15] The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
    Barron-Millar, Ben
    Ogle, Laura
    Mells, George
    Flack, Steven
    Badrock, Jonathan
    Sandford, Richard
    Kirby, John
    Palmer, Jeremy
    Jopson, Laura
    Brain, John
    Smith, Graham R.
    Rushton, Steve
    Hegade, Vinod S.
    Jones, Rebecca
    Rushbrook, Simon
    Thorburn, Douglas
    Ryder, Steve
    Hirschfield, Gideon
    Dyson, Jessica K.
    Jones, David E. J.
    HEPATOLOGY, 2021, 74 (06) : 3269 - 3283
  • [16] Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis
    Harms, Maren H.
    van Buuren, Henk R.
    Corpechot, Christophe
    Thorburn, Douglas
    Janssen, Harry L. A.
    Lindor, Keith D.
    Hirschfield, Gideon M.
    Pares, Albert
    Floreani, Annarosa
    Mayo, Marlyn J.
    Invernizzi, Pietro
    Battezzati, Pier Maria
    Nevens, Frederik
    Ponsioen, Cyriel Y.
    Mason, Andrew L.
    Kowdley, Kris, V
    Lammers, Willem J.
    Hansen, Bettina E.
    van der Meer, Adriaan J.
    JOURNAL OF HEPATOLOGY, 2019, 71 (02) : 357 - 365
  • [17] A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid
    Li, Chunlei
    Zheng, Kunyu
    Chen, Yiran
    He, Chengmei
    Liu, Suying
    Yang, Yunjiao
    Li, Mengtao
    Zeng, Xiaofeng
    Wang, Li
    Zhang, Fengchun
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2022, 13
  • [18] The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis
    Kawata, Kazuhito
    Joshita, Satoru
    Shimoda, Shinji
    Yamashita, Yuki
    Yamashita, Maho
    Kitsugi, Kensuke
    Takatori, Shingo
    Ohta, Kazuyoshi
    Ito, Jun
    Shimoyama, Shin
    Noritake, Hidenao
    Suda, Takafumi
    Harada, Kenichi
    HEPATOLOGY RESEARCH, 2021, 51 (01) : 80 - 89
  • [19] Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion
    Yang, Chunmei
    Guo, Guanya
    Li, Bo
    Zheng, Linhua
    Sun, Ruiqing
    Wang, Xiufang
    Deng, Juan
    Jia, Gui
    Zhou, Xia
    Cui, Lina
    Guo, Changcun
    Zhou, Xinmin
    Leung, Patrick S. C.
    Gershwin, M. Eric
    Shang, Yulong
    Han, Ying
    HEPATOLOGY INTERNATIONAL, 2023, 17 (01) : 237 - 248
  • [20] Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study
    Chang, Jong-In
    Kim, Jung Hee
    Sinn, Dong Hyun
    Cho, Ju-Yeon
    Kim, Kwang Min
    Oh, Joo Hyun
    Park, Yewan
    Sohn, Won
    Goh, Myung Ji
    Kang, Wonseok
    Gwak, Geum-Youn
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung-Woon
    GUT AND LIVER, 2023, 17 (04) : 620 - 628